{"product_id":"cardiac-troponin-diagnostics-forecasts-and-opportunities-to-2025","title":"Cardiac Troponin Diagnostics-Forecasts and Opportunities to 2025","description":"\u003cp\u003eCardiac Troponin Diagnostics-Forecasts and Opportunities to 2025\u003c\/p\u003e \n\n\n\n\u003cp\u003eCardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits\u003c\/p\u003e\n\n\u003cp\u003ethat can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market.\u003c\/p\u003e\n\n\n\n\u003cp\u003eHospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.\u003c\/p\u003e\n\n\n\n\u003cp\u003eIn this report, Frost \u0026amp; Sullivan overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians’ offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and\u003c\/p\u003e\n\n\u003cp\u003ehs-cTn tests.\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe report also includes the following:\u003c\/p\u003e\n\n\u003cp\u003e• Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe,\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific, and the rest of the world)\u003c\/p\u003e\n\n\u003cp\u003e• Challenges and drivers\u003c\/p\u003e\n\n\u003cp\u003e• Competitive landscape, including company market share for lab-based tests and POCT\u003c\/p\u003e\n\n\u003cp\u003e• Future trends and growth opportunities for stakeholders\u003c\/p\u003e\n\n\n\n\u003cp\u003eNorth America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. Frost \u0026amp; Sullivan’s research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"November, 2022 \/ 62 Pages \/ MCW16233823","offer_id":47650830778674,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/cardiac-troponin-diagnostics-forecasts-and-opportunities-to-2025","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}